SynchroMed brings no pain relief for Medtronic
This article was originally published in Clinica
Medtronic has agreed to the US FDA’s demands to stop making and distributing the SynchroMed II implantable infusion pumps, except in limited circumstances, until the company corrects quality system violations identified by the agency.
You may also be interested in...
Medtronic Dodges Two Of Three Claims In Pain-Pump Suit
An Indiana federal judge axed two components of a patient’s lawsuit against Medtronic, while allowing a manufacturing defect complaint to move forward.
SISTERS Data Could Lift Medtronic's SynchroMed II From Recall Repercussions
The published results of the SISTERS trial demonstrate intrathecal baclofen (ITB) therapy with the recently redesigned SynchroMed II reduces spasticity-related pain and improves quality of life more than conventional medical management with oral antispastic medications in post-stroke patients suffering spasticity. The company hopes these results can boost interest in ITB and the SynchroMed II system while it works to resolve a 2015 consent decree with the FDA related to malfunctions with a previous version of the device.
Medtronic Issues UK Warning On Implantable Pump Safety
The field safety notice revealed two patient deaths and five incidents of over-infusion tied to Medtronic's SynchroMed II pump. The pump was removed from the US market under a 2015 consent decree.